UCB Achieves Important Regulatory Milestone for Bimekizumab
Go back to UCB Achieves Important Regulatory Milestone for Bimekizumab| (NYSE: UCB) | Delayed: 35.79 -0.76 (2.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.55 | 52 Week High | $ | |||
| Open | $36.42 | 52 Week Low | $ | |||
| Day High | $36.55 | P/E | N/A | |||
| Day Low | $35.21 | EPS | $ | |||
| Volume | 420,087 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 127.30 +1.30 (1.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.00 | 52 Week High | $46.25 | |||
| Open | $128.28 | 52 Week Low | $32.74 | |||
| Day High | $128.28 | P/E | N/A | |||
| Day Low | $126.99 | EPS | $0.00 | |||
| Volume | 23,193 | |||||
